他们的救命药，退出了中国市场

Core Viewpoint - Recordati's subsidiary, Recondi, has announced its exit from the Chinese market, ceasing all operations and services, which has raised concerns among patients and healthcare professionals regarding the availability of rare disease medications [2][3][4]. Company Overview - Recondi, established in 2021, focused on rare diseases and had three approved drugs in China, two of which were commercialized [19][20]. - The company experienced rapid expansion but faced challenges in achieving profitability, leading to its decision to exit the market [4][21]. Market Dynamics - The exit was influenced by recent market and regulatory developments, particularly the rejection of the application for the inclusion of the drug Ozolisat in the national medical insurance directory [2][3][9]. - Despite the government's efforts to increase support for rare diseases, including the inclusion of approximately 100 rare disease drugs in the national insurance directory since 2018, Recondi's products did not gain entry [9][19]. Product Details - Ozolisat, a key product for treating Cushing's syndrome, was priced at 8,008 yuan per box, significantly lower than global prices but still unaffordable for many patients [8][10]. - The other product, Kaguamin, had already faced competition from generic alternatives, impacting its sales performance [4][7]. Patient Impact - The withdrawal of Recondi has left many patients without access to critical medications, with some expressing disappointment and concern over the lack of alternatives [2][4][14]. - The high costs of available treatments have made it difficult for patients to afford necessary care, with many relying on insurance coverage that has not materialized [10][11][12]. Future Considerations - Recondi's exit highlights the challenges faced by companies in the rare disease sector, including high development costs, limited patient populations, and the need for effective market education [21][22]. - The company has stated it will continue to collaborate with healthcare professionals and patient advocacy groups to mitigate the impact of its exit on patients [18].